Asciminib - nová možnost v léčbě CML
| Title in English | Asciminib - a new option in the treatment of CML |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| web | https://www.farmakoterapie.cz/c7503/asciminib-nova-moznost-v-lecbe-cml |
| Keywords | chronic myeloid leukaemia; tyrosine kinase inhibitors; asciminib; STAMP inhibitor |
| Attached files | |
| Description | Prognosis of patients with chronic myeloid leukaemia (CML) has changed radically over the past 20 years. This was due to the introduction of targeted therapy with imatinib, the first tyrosine kinase inhibitor (TKI), followed by other 2nd and 3rd generation TKIs. The life expectancy of CML patients treated with TKIs is close to that of the general population. However, TKI treatment is not without risk. On the one hand, there is the development of resistance to the TKI followed by loss of treatment response, on the other hand, there are the known risks of adverse events which can affect the quality of life or even be life-threatening. Therefore, asciminib, a new TKIm has been introduced to the clinical practice. With its new mechanism of action, asciminib shows a potential to reinduce the treatment response in patients resistant to previous TKIs while exhibiting an improved safety profile. Phase I and III studies have shown its efficacy and safety in patients after at least 2 previous lines of TKI therapy. Based on a phase III study (ASCEMBL), asciminib has already been registered for use in patients in the US and Europe (including the Czech Republic). Studies are also underway to investigate both the possibility of combination therapy of asciminib with other TKIs in pretreated patients and the possibility of asciminib monotherapy in newly diagnosed CML. |
| Related projects: |